Gocovri (amantadine) more than doubled the daily time on levodopa-based therapies without any dyskinesia — involuntary, uncontrolled movements — in people with Parkinson’s disease compared to those given a placebo, an analysis of data from two Phase…
Gocovri (amantadine) has been approved by the U.S. Food and Drug Administration (FDA) as an add-on therapy for off episodes in people with Parkinson’s disease. Adamas Pharmaceuticals, which developed the therapy, announced its approval in the U.S. for Parkinson’s patients currently taking levodopa and/or carbidopa. Off…
Gocovri (amantadine) can reduce the number and duration of off episodes — periods during which levodopa-based treatments cease to be effective and motor symptoms return — as well as ease dyskinesia in patients with Parkinson’s, according to a post-hoc analysis of Phase 3 trials. These findings were presented…
Gocovri (amantadine) can effectively reduce the number and duration of “off” periods and dyskinesia (uncontrolled movement) episodes in Parkinson’s patients under long-term levodopa treatment, leading to a good steady “on” state, pooled Phase 3 clinical data show. These findings were reported in a study, “…
Parkinson’s disease patients treated with Gocovri (amantadine) experienced a 41 percent decrease in levodopa-induced dyskinesia compared to 14 percent of healthy people who took placebos. That analysis of two Phase 3 trials are summarized in the study “Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for…
Get regular updates to your inbox.
